How allosteric modulators like SBI-553 reshape the GPCR-transducer interface to program precise signaling outcomes

G protein-coupled receptors (GPCRs) represent the largest family of drug targets, yet developing therapies that activate therapeutic pathways while avoiding side effects remains a formidable challenge. Most current drugs bind to the orthosteric site, often activating all downstream effectors—G proteins and $\beta$-arrestins—indiscriminately. This lack of selectivity contributes to on-target toxicity, as the therapeutic benefit often arises from one signaling cascade while adverse events stem from another. Although “biased signaling” has long been a goal, the structural determinants governing how a receptor selects one G protein subtype over another (e.g., Gq vs. GoA) have remained elusive, stalling the rational design of pathway-specific medicines.

In a significant advance, researchers recently elucidated the mechanism by which small molecules can dictate G protein preference. By focusing on the neurotensin receptor 1 (NTSR1), the team demonstrated that the allosteric modulator SBI-553 does not merely inhibit signaling but actively sculpts the intracellular transducer pocket. Using cryo-electron microscopy and computational modeling, they revealed that SBI-553 acts simultaneously as a “molecular bumper” and a “molecular glue.” It binds within the receptor’s core, creating a steric block that prevents the engagement of specific G proteins (like Gq) while stabilizing an alternative “open” receptor conformation that energetically favors others (like GoA). This selectivity is driven by the ability of the G protein’s C-terminal tail to adapt to the modified pocket geometry.

These findings establish a proof of principle for the rational engineering of signaling bias. By making minor chemical modifications to the SBI-553 scaffold, the authors successfully inverted the receptor’s selectivity profile, creating variants that favored Gq over GoA. This confirms that the conserved intracellular pocket of GPCRs can be targeted to program precise signaling outcomes. This structure-based strategy offers a reproducible blueprint for designing “biased allosteric modulators” (BAMs) across the GPCR superfamily, potentially ushering in a new generation of drugs that decouple therapeutic efficacy from unwanted side effects.